FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W60966954> ?p ?o ?g. }

• W60966954 endingPage "4" @default.
• W60966954 startingPage "32" @default.
• W60966954 abstract "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been studied primarily on a 3-week schedule as a 3-, 24-, or 96-hour infusion at doses ranging from 135 to 250 mg/m2. The observed toxicity profile seems to be both dose and schedule dependent. Dose densification of paclitaxel given weekly over 6 weeks on a split-dose schedule for an overall increase in dose intensity was thought to improve the therapeutic index of paclitaxel in a variety of advanced malignancies and to be suitable for outpatient administration. For this study, chemotherapy consisted of a weekly 1-hour infusion of paclitaxel at a starting dose of 40 mg/m2/wk for 6 weeks, followed by a 2- to 3-week interval. Paclitaxel dosage was escalated in 10 mg/m2/wk increments in subsequent patients, to a maximum dosage of 90 mg/m2/wk. Intravenous dexamethasone, cimetidine, clemastine, and ondansetron were administered immediately before the paclitaxel infusion. Fifty patients participated in the study. The male to female ratio was 21 to 29, the median age was 53.2 years (age range, 33 to 74), and the median performance status was 1. All patients were chemotherapeutically pretreated. Overall response included five complete responses (10%), 15 partial responses (30%), 19 no change (38%), and 11 disease progressions (22%). Median dose intensity was 410 mg/m2/6 wk (range, 200 to 540 mg/m2/6 wk). Hematologic toxicity was mild, with no grade 3 or 4 toxicity up to 90 mg/m2/wk. No hypersensitivity reactions or neurologic or cardiac toxicities were documented. Dose-densified, weekly paclitaxel is concluded to be active in a variety of pretreated tumor entities. The overall low hematologic and peripheral toxicity profile suggests that further dose intensification of weekly paclitaxel and/or combination with other cytotoxic agents (eg, cisplatin/carboplatin, ifosfamide, etoposide) may be warranted. Paclitaxel can be given safely in the outpatient setting. Paclitaxel 90 mg/m2/wk is recommended for single-agent treatment. Dose-densified paclitaxel may be considered a valuable and promising alternative to standard 3-week treatment, with further options possible in combination chemotherapy." @default.
• W60966954 created "2016-06-24" @default.
• W60966954 creator A5023982431 @default.
• W60966954 creator A5027292460 @default.
• W60966954 creator A5038938008 @default.
• W60966954 creator A5072105330 @default.
• W60966954 date "1996-12-01" @default.
• W60966954 modified "2023-09-23" @default.
• W60966954 title "Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial." @default.
• W60966954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9007118" @default.
• W60966954 hasPublicationYear "1996" @default.
• W60966954 type Work @default.
• W60966954 sameAs 60966954 @default.
• W60966954 citedByCount "19" @default.
• W60966954 countsByYear W609669542013 @default.
• W60966954 countsByYear W609669542015 @default.
• W60966954 countsByYear W609669542021 @default.
• W60966954 crossrefType "journal-article" @default.
• W60966954 hasAuthorship W60966954A5023982431 @default.
• W60966954 hasAuthorship W60966954A5027292460 @default.
• W60966954 hasAuthorship W60966954A5038938008 @default.
• W60966954 hasAuthorship W60966954A5072105330 @default.
• W60966954 hasConcept C126322002 @default.
• W60966954 hasConcept C126894567 @default.
• W60966954 hasConcept C141071460 @default.
• W60966954 hasConcept C2776694085 @default.
• W60966954 hasConcept C2777292972 @default.
• W60966954 hasConcept C29730261 @default.
• W60966954 hasConcept C42219234 @default.
• W60966954 hasConcept C71924100 @default.
• W60966954 hasConcept C90924648 @default.
• W60966954 hasConceptScore W60966954C126322002 @default.
• W60966954 hasConceptScore W60966954C126894567 @default.
• W60966954 hasConceptScore W60966954C141071460 @default.
• W60966954 hasConceptScore W60966954C2776694085 @default.
• W60966954 hasConceptScore W60966954C2777292972 @default.
• W60966954 hasConceptScore W60966954C29730261 @default.
• W60966954 hasConceptScore W60966954C42219234 @default.
• W60966954 hasConceptScore W60966954C71924100 @default.
• W60966954 hasConceptScore W60966954C90924648 @default.
• W60966954 hasIssue "6 Suppl 16" @default.
• W60966954 hasLocation W609669541 @default.
• W60966954 hasOpenAccess W60966954 @default.
• W60966954 hasPrimaryLocation W609669541 @default.
• W60966954 hasRelatedWork W1994918739 @default.
• W60966954 hasRelatedWork W2074884814 @default.
• W60966954 hasRelatedWork W2362265618 @default.
• W60966954 hasRelatedWork W2365230339 @default.
• W60966954 hasRelatedWork W2372651819 @default.
• W60966954 hasRelatedWork W2387021862 @default.
• W60966954 hasRelatedWork W2564135479 @default.
• W60966954 hasRelatedWork W2912794087 @default.
• W60966954 hasRelatedWork W2913291294 @default.
• W60966954 hasRelatedWork W3014652937 @default.
• W60966954 hasVolume "23" @default.
• W60966954 isParatext "false" @default.
• W60966954 isRetracted "false" @default.
• W60966954 magId "60966954" @default.
• W60966954 workType "article" @default.